KINASE INHIBITORS
Cardiovascular Toxicity in Cancer Patients Treated with Tyrosine Kinase Inhibitors: A Real-World Single-Center Experience
In this retrospective, observational study of 55 patients with who received either nilotinib, dasatinib, or ponatinib (Group A) or imatinib (Group B), myocardial ischemia, peripheral artery disease, deep vein thrombosis, and pleural effusion were significantly more frequent in Group A than Group B (P = .044).
Oncology
